126085-89-0 Usage
General Description
3-Methyl-5-(tributylstannyl)isoxazole is a chemical compound that consists of a five-membered heterocyclic ring containing one nitrogen and one oxygen atom, with a methyl group and tributylstannyl group attached to the ring. It is commonly used as a synthon in organic synthesis, particularly in the construction of complex organic molecules. The tributylstannyl group can undergo substitution reactions to introduce the isoxazole ring into various organic compounds, making it a valuable building block in the field of medicinal chemistry and drug discovery. However, due to the toxic nature of organotin compounds, careful handling and disposal are required when working with 3-methyl-5-(tributylstannyl)isoxazole.
Check Digit Verification of cas no
The CAS Registry Mumber 126085-89-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,6,0,8 and 5 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 126085-89:
(8*1)+(7*2)+(6*6)+(5*0)+(4*8)+(3*5)+(2*8)+(1*9)=130
130 % 10 = 0
So 126085-89-0 is a valid CAS Registry Number.
126085-89-0Relevant articles and documents
The synthesis of epiboxidine and related analogues as potential pharmacological agents
Kulu, Irem,Ocal, Nuket
, p. 2054 - 2060 (2011)
Methyl epiboxidine-N-carboxylate (8) was synthesized from 7 under reductive Heck conditions (Scheme 2). The C-C coupling of the new epiboxidine analog 9 with aryl and heteroaryl halides gave by hydroarylation C-aryl, N-(3-methylisoxazol-5-yl)-substituted
PYRIDONE COMPOUND AS C-MET INHIBITOR
-
Paragraph 0202-0204, (2019/08/27)
Disclosed in the present invention is a type of pyridone compounds as c-met inhibitors, and specifically disclosed is a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof.
HYDROXYL PURINE COMPOUNDS AND USE THEREOF
-
Paragraph 0231; 0232; 0233, (2018/04/05)
Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNFα inhibitors, in particular, the compounds as shown in formula (I), or tautomers thereof or pharmaceutically acceptable salts thereof.
